Open Access. Powered by Scholars. Published by Universities.®

Engineering Commons™

Open Access. Powered by Scholars. Published by Universities.®

Engineering Conferences International

Discipline
Keyword
Publication Year
Publication
File Type

Articles 1861 - 1890 of 2957

Full-Text Articles in Engineering

Plant-Made Influenza Virus-Like Particles: For Pandemic And Beyond, Nathalie Charland May 2012

Plant-Made Influenza Virus-Like Particles: For Pandemic And Beyond, Nathalie Charland

Vaccine Technology IV

No abstract provided.


Mutiply Activated Vlp Influenza Vaccines, James Swartz, Yuan Lu, John Welsh, Wei Chan May 2012

Mutiply Activated Vlp Influenza Vaccines, James Swartz, Yuan Lu, John Welsh, Wei Chan

Vaccine Technology IV

No abstract provided.


Novel Glycoconjugate Vaccines Based On Rationally Designed Synthetic Carbohydrate Antigens, Stwewart Campbell May 2012

Novel Glycoconjugate Vaccines Based On Rationally Designed Synthetic Carbohydrate Antigens, Stwewart Campbell

Vaccine Technology IV

No abstract provided.


Purification Of Cell-Based Influenza H5n1 Viruses By Liquid Chromatography Technologies, Alan Yung-Chih Hu May 2012

Purification Of Cell-Based Influenza H5n1 Viruses By Liquid Chromatography Technologies, Alan Yung-Chih Hu

Vaccine Technology IV

No abstract provided.


Flunisyn: Advanced Development Of A Synthetic Universal Influenza T-Cell Vaccine, Campbell Bunce May 2012

Flunisyn: Advanced Development Of A Synthetic Universal Influenza T-Cell Vaccine, Campbell Bunce

Vaccine Technology IV

No abstract provided.


Viral Sensitizer Technology Improves Yield Of Modified Vaccinia Ankara From Available Cell Substrates, Facrice Le Boeuf May 2012

Viral Sensitizer Technology Improves Yield Of Modified Vaccinia Ankara From Available Cell Substrates, Facrice Le Boeuf

Vaccine Technology IV

No abstract provided.


Monolithic Columns For Purification And In-Process Control Of Viruses And Virus-Like Particles, Lidija Urbas, Milos Barut May 2012

Monolithic Columns For Purification And In-Process Control Of Viruses And Virus-Like Particles, Lidija Urbas, Milos Barut

Vaccine Technology IV

No abstract provided.


Endotoxin-Free E. Coli Hosts For Vaccine Discovery And Production, David Bramhill May 2012

Endotoxin-Free E. Coli Hosts For Vaccine Discovery And Production, David Bramhill

Vaccine Technology IV

No abstract provided.


Bacterium-Like Particles As Delivery Vehicles For Multimeric Antigens, Kees Leenhouts May 2012

Bacterium-Like Particles As Delivery Vehicles For Multimeric Antigens, Kees Leenhouts

Vaccine Technology IV

No abstract provided.


Utilizing ‘Omics Tools To Investigate The Impact Of Process Changes On Product Quality In Cell Culture-Based Influenza Vaccine Production, E. Rapp, J. Rodig, J. Schwarzer, D. Hoeper, R. Hennig, Y. Genzel, U. Reichl May 2012

Utilizing ‘Omics Tools To Investigate The Impact Of Process Changes On Product Quality In Cell Culture-Based Influenza Vaccine Production, E. Rapp, J. Rodig, J. Schwarzer, D. Hoeper, R. Hennig, Y. Genzel, U. Reichl

Vaccine Technology IV

No abstract provided.


Suspension Vero Cells (Svero) For Poliovirus Production: Effect Of Culture Passage On Growth Kinetics And Productivity, Guillermina Forno May 2012

Suspension Vero Cells (Svero) For Poliovirus Production: Effect Of Culture Passage On Growth Kinetics And Productivity, Guillermina Forno

Vaccine Technology IV

No abstract provided.


Systematically Characterizing Adventitious Agent Tests For Biologics, Rebecca Sheets May 2012

Systematically Characterizing Adventitious Agent Tests For Biologics, Rebecca Sheets

Vaccine Technology IV

No abstract provided.


Automation And Multiplexing Of Immunoassays: Improving Precision And Throughput, Ilia Tikhonov May 2012

Automation And Multiplexing Of Immunoassays: Improving Precision And Throughput, Ilia Tikhonov

Vaccine Technology IV

No abstract provided.


Microbial Fermentation: New Tools To Speed-Up Vaccine Antigen Development And Increase Process Knowledge, Catherine Jourdat May 2012

Microbial Fermentation: New Tools To Speed-Up Vaccine Antigen Development And Increase Process Knowledge, Catherine Jourdat

Vaccine Technology IV

No abstract provided.


Building Pandemic Preparedness Through A Sustainable Enterprise For Influenza Vaccines, Robert Huebner May 2012

Building Pandemic Preparedness Through A Sustainable Enterprise For Influenza Vaccines, Robert Huebner

Vaccine Technology IV

No abstract provided.


High Cell Density Cultivations For Influenza Virus Production Using Suspension Cells, Y. Genzel, T. Vogel, J. Buck, I. Behrendt, G. Schiedner, I. Jordan, U. Reichl May 2012

High Cell Density Cultivations For Influenza Virus Production Using Suspension Cells, Y. Genzel, T. Vogel, J. Buck, I. Behrendt, G. Schiedner, I. Jordan, U. Reichl

Vaccine Technology IV

No abstract provided.


Rmce-Based Sf9 Cell Factory For Production Of Multi-Meric Vlps, Ana Teixera May 2012

Rmce-Based Sf9 Cell Factory For Production Of Multi-Meric Vlps, Ana Teixera

Vaccine Technology IV

No abstract provided.


Bacterial Expression Of A Vlp Sub-Unit For Rapid And Cheap Influenza Vaccination, Anton Middelberg May 2012

Bacterial Expression Of A Vlp Sub-Unit For Rapid And Cheap Influenza Vaccination, Anton Middelberg

Vaccine Technology IV

No abstract provided.


Developing A Suite Of Analytics To Support Process Development For The Manufacture Of Polysaccharides, Aaron Noyes, Ranga Godavarti, Nigel Titchener-Hooker, Jonathan Coffman, Tarit Mukhopadhyay May 2012

Developing A Suite Of Analytics To Support Process Development For The Manufacture Of Polysaccharides, Aaron Noyes, Ranga Godavarti, Nigel Titchener-Hooker, Jonathan Coffman, Tarit Mukhopadhyay

Vaccine Technology IV

No abstract provided.


Cervical Cancer Immunotherapy: Induction Of Hpv Specific Ctls In Human Volunteers After Vgx-3100 Immunization, Niranjan Sardesai May 2012

Cervical Cancer Immunotherapy: Induction Of Hpv Specific Ctls In Human Volunteers After Vgx-3100 Immunization, Niranjan Sardesai

Vaccine Technology IV

No abstract provided.


A Protein-Free Process And Product Protection System, Stephen Ward May 2012

A Protein-Free Process And Product Protection System, Stephen Ward

Vaccine Technology IV

No abstract provided.


Functional Genomics As A Tool To Define A Molecular Signature Of Effective Vaccination Against Foot And Mouth Disease Virus, Jose Chabalgoity May 2012

Functional Genomics As A Tool To Define A Molecular Signature Of Effective Vaccination Against Foot And Mouth Disease Virus, Jose Chabalgoity

Vaccine Technology IV

No abstract provided.


Oncolytic Viruses As Cancer Therapies, Stephen Rusell May 2012

Oncolytic Viruses As Cancer Therapies, Stephen Rusell

Vaccine Technology IV

No abstract provided.


Chimpanzee Ad Vector Technology Platform For Prophylactic And Therapeutic Genetic Vaccine Applications, Stefano Colloca May 2012

Chimpanzee Ad Vector Technology Platform For Prophylactic And Therapeutic Genetic Vaccine Applications, Stefano Colloca

Vaccine Technology IV

No abstract provided.


Challenges In Optimizing Formulations For Multi- Antigen Vaccines, Lakshmi Khandke May 2012

Challenges In Optimizing Formulations For Multi- Antigen Vaccines, Lakshmi Khandke

Vaccine Technology IV

No abstract provided.


A New Successful Vaccine Against Babesiosis: Any Use For Malaria?, Thep Schetters May 2012

A New Successful Vaccine Against Babesiosis: Any Use For Malaria?, Thep Schetters

Vaccine Technology IV

No abstract provided.


The Cmc Challenges In Developing An Oncolytic Immunotherapy, Colin Love May 2012

The Cmc Challenges In Developing An Oncolytic Immunotherapy, Colin Love

Vaccine Technology IV

No abstract provided.


High Throughput Formulation Design For A Stable Lyophilized Virus-Like Particle Vaccine Against Group A Streptococcu, Yap Chuan May 2012

High Throughput Formulation Design For A Stable Lyophilized Virus-Like Particle Vaccine Against Group A Streptococcu, Yap Chuan

Vaccine Technology IV

No abstract provided.


Process Development For A Peptide Conjugated Qbetavirus Like Particle (Vlp) Vaccine, Jennifer Thorn May 2012

Process Development For A Peptide Conjugated Qbetavirus Like Particle (Vlp) Vaccine, Jennifer Thorn

Vaccine Technology IV

No abstract provided.


Formulation And Stability Of A Chikungunya Virus-Like Particle (Chikv Vlp) Based Vaccine, Rhicard Schwartz May 2012

Formulation And Stability Of A Chikungunya Virus-Like Particle (Chikv Vlp) Based Vaccine, Rhicard Schwartz

Vaccine Technology IV

No abstract provided.